Sell AstraZeneca, says UBS, which upgrades European rivals including GSK

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

Previous post Ten-year Treasury tops 4% as central banks try to cool traders’ rate-cut optimism
Next post Hugo Boss shares tumble on earnings miss forecast